{"title":"胞胆碱与维生素B12联合使用是否有利于角膜交联后角膜神经的愈合?","authors":"Metin Unlu, Furkan Ozer, Esra Sahin Aslan, Hidayet Sener, Kuddusi Erkilic","doi":"10.1007/s10792-025-03433-5","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the effect of topical citicoline, vitamin B12 and hyaluronic acid (OMK2 eye drops; Omikron Italia Srl, Italy) on the healing of corneal nerve after corneal cross-linking (CXL) treatment in patients with keratoconus (KC).</p><p><strong>Methods: </strong>A total of 44 eyes of 22 patients with KC who underwent CXL were included in this prospective study. After CXL, one eye of these patients received OMK2 eye drop and standard post-CXL treatment (OMK2 group), while the fellow eye received only standard post-CXL treatment (control group). The following parameters were analyzed in the pre- and post-CXL procedure periods (1st, 3rd and 6th months): corneal sensitivity, tear film stability, central corneal thickness (CCT), and the corneal sub-basal nerve plexus (sbNP) parameters (including corneal nerve fiber density [CNFD], corneal nerve branch density [CNBD], corneal nerve fiber length [CNFL], corneal total branch density [CTBD], corneal nerve fiber area [CNFA], corneal nerve fiber width [CNFW]).</p><p><strong>Results: </strong>Following CXL, a comparison of the baseline and month 6 data revealed that CNFA decreased in the control group (p < 0.001) and did not differ in the OMK2 group (p = 0.283). Other corneal sbNP parameters exhibited a decrease when comparing baseline and 6 months in each group (all p < 0.05). In addition, CCT in the OMK2 group was not significantly different between baseline and month 6 (p = 0.052). However, a decline in CCT of the control groups was observed during this specified time interval (p = 0.009). Corneal sensitivity or tear film stability parameters did not differ significantly between groups at any time point or over time within each group (all p > 0.05).</p><p><strong>Conclusion: </strong>The use of OMK2 eye drop after CXL may provide more stable CNFA. In addition, it may also provide faster recovery in CCT.</p>","PeriodicalId":14473,"journal":{"name":"International Ophthalmology","volume":"45 1","pages":"54"},"PeriodicalIF":1.4000,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Can the combination of citicoline and vitamin B12 be beneficial in the healing of corneal nerves after corneal cross-linking?\",\"authors\":\"Metin Unlu, Furkan Ozer, Esra Sahin Aslan, Hidayet Sener, Kuddusi Erkilic\",\"doi\":\"10.1007/s10792-025-03433-5\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>To evaluate the effect of topical citicoline, vitamin B12 and hyaluronic acid (OMK2 eye drops; Omikron Italia Srl, Italy) on the healing of corneal nerve after corneal cross-linking (CXL) treatment in patients with keratoconus (KC).</p><p><strong>Methods: </strong>A total of 44 eyes of 22 patients with KC who underwent CXL were included in this prospective study. After CXL, one eye of these patients received OMK2 eye drop and standard post-CXL treatment (OMK2 group), while the fellow eye received only standard post-CXL treatment (control group). The following parameters were analyzed in the pre- and post-CXL procedure periods (1st, 3rd and 6th months): corneal sensitivity, tear film stability, central corneal thickness (CCT), and the corneal sub-basal nerve plexus (sbNP) parameters (including corneal nerve fiber density [CNFD], corneal nerve branch density [CNBD], corneal nerve fiber length [CNFL], corneal total branch density [CTBD], corneal nerve fiber area [CNFA], corneal nerve fiber width [CNFW]).</p><p><strong>Results: </strong>Following CXL, a comparison of the baseline and month 6 data revealed that CNFA decreased in the control group (p < 0.001) and did not differ in the OMK2 group (p = 0.283). Other corneal sbNP parameters exhibited a decrease when comparing baseline and 6 months in each group (all p < 0.05). In addition, CCT in the OMK2 group was not significantly different between baseline and month 6 (p = 0.052). However, a decline in CCT of the control groups was observed during this specified time interval (p = 0.009). Corneal sensitivity or tear film stability parameters did not differ significantly between groups at any time point or over time within each group (all p > 0.05).</p><p><strong>Conclusion: </strong>The use of OMK2 eye drop after CXL may provide more stable CNFA. In addition, it may also provide faster recovery in CCT.</p>\",\"PeriodicalId\":14473,\"journal\":{\"name\":\"International Ophthalmology\",\"volume\":\"45 1\",\"pages\":\"54\"},\"PeriodicalIF\":1.4000,\"publicationDate\":\"2025-01-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Ophthalmology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s10792-025-03433-5\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10792-025-03433-5","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
目的:评价胞胆碱、维生素B12、透明质酸(OMK2)滴眼液外用的疗效;Omikron Italia Srl, Italy)对圆锥角膜(KC)患者角膜交联(CXL)治疗后角膜神经愈合的影响。方法:对22例行CXL的KC患者的44只眼进行前瞻性研究。在CXL后,患者的一只眼接受OMK2滴眼液和标准的CXL后治疗(OMK2组),而另一只眼只接受标准的CXL后治疗(对照组)。分析cxl手术前后(1、3、6个月)角膜敏感性、泪膜稳定性、角膜中央厚度(CCT)、角膜基底下神经丛(sbNP)参数(包括角膜神经纤维密度[CNFD]、角膜神经分支密度[CNBD]、角膜神经纤维长度[CNFL]、角膜总分支密度[CTBD]、角膜神经纤维面积[CNFA]、角膜神经纤维宽度[CNFW])。结果:CXL后,基线和第6个月数据的比较显示对照组CNFA下降(p < 0.05)。结论:CXL术后使用OMK2滴眼液可提供更稳定的CNFA。此外,它还可以在CCT中提供更快的恢复。
Can the combination of citicoline and vitamin B12 be beneficial in the healing of corneal nerves after corneal cross-linking?
Purpose: To evaluate the effect of topical citicoline, vitamin B12 and hyaluronic acid (OMK2 eye drops; Omikron Italia Srl, Italy) on the healing of corneal nerve after corneal cross-linking (CXL) treatment in patients with keratoconus (KC).
Methods: A total of 44 eyes of 22 patients with KC who underwent CXL were included in this prospective study. After CXL, one eye of these patients received OMK2 eye drop and standard post-CXL treatment (OMK2 group), while the fellow eye received only standard post-CXL treatment (control group). The following parameters were analyzed in the pre- and post-CXL procedure periods (1st, 3rd and 6th months): corneal sensitivity, tear film stability, central corneal thickness (CCT), and the corneal sub-basal nerve plexus (sbNP) parameters (including corneal nerve fiber density [CNFD], corneal nerve branch density [CNBD], corneal nerve fiber length [CNFL], corneal total branch density [CTBD], corneal nerve fiber area [CNFA], corneal nerve fiber width [CNFW]).
Results: Following CXL, a comparison of the baseline and month 6 data revealed that CNFA decreased in the control group (p < 0.001) and did not differ in the OMK2 group (p = 0.283). Other corneal sbNP parameters exhibited a decrease when comparing baseline and 6 months in each group (all p < 0.05). In addition, CCT in the OMK2 group was not significantly different between baseline and month 6 (p = 0.052). However, a decline in CCT of the control groups was observed during this specified time interval (p = 0.009). Corneal sensitivity or tear film stability parameters did not differ significantly between groups at any time point or over time within each group (all p > 0.05).
Conclusion: The use of OMK2 eye drop after CXL may provide more stable CNFA. In addition, it may also provide faster recovery in CCT.
期刊介绍:
International Ophthalmology provides the clinician with articles on all the relevant subspecialties of ophthalmology, with a broad international scope. The emphasis is on presentation of the latest clinical research in the field. In addition, the journal includes regular sections devoted to new developments in technologies, products, and techniques.